Global Transthyretin Amyloidosis Treatment Market

Transthyretin Amyloidosis Treatment Market is expected to reach USD 13.58 Bn. at a CAGR of 12.7 during the forecast period 2032.

Amyloidoses, range of protein disorders, are characterized by insoluble extracellular fibril deposits that get deposited in organs and cause organ dysfunction. Transthyretin is one such protein that can cause transthyretin amyloidosis. Treatments of amyloidosis are used to reduce the amyloidosis and limit amyloid protein production. It happens due to various causes like hereditary factors, bone marrow disorder, or even due to some other underlying sickness. To know about the Research Methodology :- Request Free Sample Report

The transthyretin amyloidosis treatment market dynamics are thoroughly studied and explained in the MMR report, which helps to understand emerging market trends, drivers, restraints, opportunities, and challenges at the global and regional level for the TTR amyloidosis treatment market globally. The market is likely to experience robust development post the launch of transthyretin therapeutic drugs, primarily because of growing American African population, growing healthcare spending, and accelerating financial growth. On the flip side, lack of information on this condition and insufficiency of advanced diagnostic methods in middle income economies are significant TTR amyloidosis market barriers.

According to the American Society of Clinical Oncology report, nearby 4000 people in the US develop amyloidosis yearly and it is usually diagnosed between people aged 50 to 65 years. There are rare cases of people in their late 20 s being detected with amyloidosis. Therefore,with an upsurge in the ageing population, the market for transthyretin (TTR) amyloidosis treatment will also grow.

The MMR report covers the segments in the transthyretin amyloidosis treatment market such as treatment type, disease type, and distribution channel. Based on the disease type, hereditary transthyretin amyloidosis (hATTR) segment was valued USD xx Bn. in 2025 and is expected to reach a value of USD xx Bn by 2032, with a CAGR of xx% during the forecast period. The hATTR is caused by the misfolding of protein monomers resulting from the TTR. Mutations in the gene for TTR normally result in uncertainty of subsequent fibril formation and TTR. Hereditary transthyretin amyloidosis can be sub-classified into polyneuropathy, cardiomyopathy and mixed.

North America transthyretin amyloidosis treatment market was valued USD xx Mn. in 2025 and is expected to reach a value of USD xxMn. by 2032, with a CAGR of xx.% during 2026-2032. This is attributed to an increasing prevalence of amyloidosis between adults and the ageing & growing geriatric population, which is a significant cause for TTR disease. Such as, as per the ASCO Journal study in 2017, around 4,000 people develop amyloidosis yearly in the United States.

Europe stood as the second largest in the transthyretin amyloidosis treatment market thanks to the availability of advanced treatment services, a growing need for the better healthcare industry. Almost 60 new cases of TTR amyloidosis are recorded per year in the U.K, and the age-specific occurrence rate is among 5.1 and 12.8 per million yearly.

The MMR report also focuses on global major leading industry players of transthyretin amyloidosis treatment market providing information like company profiles, and revenue. Such as, in 2018, Alnylam Pharmaceuticals Company received the United StatesFDA (Food and Drug Administration) support for its ONPATTRO lipid complex injection RNA interference (RNAi) therapeutic - specified for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis in adults.

The objective of the report is to present a comprehensive analysis of the Global Transthyretin Amyloidosis Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

Recent Industry Developments (2025–2026)

The report also helps in understanding Global Transthyretin Amyloidosis Treatment Market dynamics, structure by analyzing the market segments and projects the Global Transthyretin Amyloidosis Treatment Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Transthyretin Amyloidosis Treatment Market make the report investor’s guide.

Scope of the Global Transthyretin Amyloidosis Treatment Market: Inquire before buying

Transthyretin Amyloidosis Treatment Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

key players / competitors profiles covered in the Transthyretin Amyloidosis Treatment Market report in strategic perspective

Alnylam Pharmaceuticals, Inc.
Pfizer, Inc.
GlaxoSmithKline Plc.
Ionis Pharmaceuticals, Inc.
Eidos Therapeutics
SOM Innovation Biotech, S.L.
Arcturus Therapeutics
Merck & Co.
AstraZeneca plc.
Prothena Corporation plc.
BridgeBio Pharma, Inc.
Akcea Therapeutics, Inc.
Intellia Therapeutics, Inc.
Bristol-Myers Squibb Company
Johnson & Johnson Services, Inc.
Takeda Pharmaceutical Company Limited
Amgen Inc.
Astellas Pharma Inc.
Acrotech Biopharma LLC
Attralus, Inc.
Oncopeptides AB
Neurimmune AG
Regeneron Pharmaceuticals, Inc.